The release of Dermatropin transdermal HGH gel is the culmination of more than 4 years of research and development into micro-dosing. Rapha Pharma previously entered into a licensing agreement with Nutritech BioPharma to utilize its proprietary technology to increase the bioavailability of transdermal HGH utilizing radiofrequency ablation.
The licensing agreement demonstrates Rapha's commitment to bringing novel delivery methods for effective micro-dosing of Active Pharmaceutical Ingredients to market, said Robert Kind, CEO Nutritech BioPharma.
Dermatropin transdermal HGH gel is the first therapy of its kind and has demonstrated safety and efficacy across the spectrum of anti-aging. We look forward to working closely with Rapha Pharma to bring Dermatropin transdermal HGH gel directly to patients, who can now increase the quality of their lives each month, Kind added.
HGH levels decline every year after age 25 so having an effective transdermal HGH gel designed to address the complex nature of anti-aging is a welcome step forward to affordable self-care.
Dermatropin transdermal HGH gel offers self-administration with safety and efficacy across a spectrum of patients, including in those who have previously tried other transdermal products marketed as HGH gel but whose molecular weight is too large to penetrate the epidermis, or worse, products marketed by unscrupulous multi-level marketing companies such as New U Life's Somaderm Gel that contain no HGH whatsoever, said Nutritech Chief Medical Officer, Stuart Keller, MD.
The current U.S. price of Dermatropin transdermal HGH Gel is $79.00 for once monthly, 5.0 ounce pump bottle. The price of Dermatropin reflects the value it brings to patients and society, affordability, and timely access to self-care on http//www.buydermatropin.com.